Adnkronos Milan, June 13 (Adnkronos Salute) – "Starting treatment with momelotinib early", a Jak inhibitor, "can lead a greater number of patients to live longer. An absolutely important fact that changes the way we approach myelofibrosis. The message is: let's start with momelotinib as early as possible in the natural history of patients".
Francesco Passamonti, director of the Complex Structure of Hematology at the Policlinico di Milano and full professor of Hematology at the University of Milan, said this while commenting on the data that emerged from the Simplify-1 clinical study and presented at the European Congress of Hematology (EHA) underway in the Lombardy capital.
Improving hemoglobin, and therefore reducing anemia that "is accompanied by worsening and dangerous symptoms for patients", is a very important point in myelofibrosis. The results of the study presented at the Eha highlight "that the percentage of patients who obtain a high hemoglobin, that is, more than 10 g/dL - specifies the expert - is in those who start treatment with momelotinib earlier".
The Simplify-1 clinical studies have shown that momelotinib, recently available in Italy, "induces great advantages compared to other Jak inhibitors. One of the main ones - Passamonti points out - is the increase in the number of patients who become transfusion-independent with the consequent reduction in the number of transfusions and the increase in "immunoglobulins to higher values".